SQZ Biotechnologies Company SQZB
Set alert
At close · Feb 5
- YTD
- 0.00%
- 1 year
- +4.35%
- Open
- 0.023
- Prev close
- 0.024
- Mkt cap
- 707.79K
- Vol
- 25.00K
- Avg vol
- 20.12K
- EPS
- -2.08
- P/E
- 0.00
More statistics
- Low
- 0.023
- High
- 0.023
News
3 weeks ago defenseworld.net
SQZ Biotechnologies Company (OTCMKTS:SQZB) Sees Large Drop in Short Interest
SQZ Biotechnologies Company (OTCMKTS:SQZB - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 6,479…
2 years ago businesswire.com
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based…
2 years ago businesswire.com
Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced the results for the proposals considered and voted upon by its shareholders at its…
2 years ago businesswire.com
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial…
3 years ago businesswire.com
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the…
3 years ago businesswire.com
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported second quarter 2023 financial results and recent…